Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 8;9(1):e12375.
doi: 10.1002/trc2.12375. eCollection 2023 Jan-Mar.

Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel

Marwan N Sabbagh  1 , Angela Taylor  2 , Douglas Galasko  3 , James E Galvin  4 , Jennifer G Goldman  5 , James B Leverenz  6 , Kathleen L Poston  7 , Bradley F Boeve  8 , David J Irwin  9 , Joseph F Quinn  10
Affiliations

Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel

Marwan N Sabbagh et al. Alzheimers Dement (N Y). .

Abstract

The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Clinical Dementia Rating scale and Alzheimer's Disease Assessment Scale-Cognitive Subscale being among the most often used instruments in AD clinical trials. In contrast, there are no validated instruments for use in clinical trials of drugs for the treatment of dementia with Lewy bodies. This poses challenges for drug development because the regulatory pathway to drug approval requires demonstrable efficacy measures. In December 2021, the Lewy Body Dementia Association advisory group met with representatives from the US Food and Drug Administration to discuss the lack of approved drugs and treatments, discernment of efficacy measures, and identification of biomarkers.

Highlights: The Lewy Body with Dementia Association convened a listening session with the US Food and Drug Administration on dementia with Lewy bodies (DLB) and clinical trial design.Gaps include DLB-specific measures, alpha synuclein biomarkers, and coexisting pathologies.DLB clinical trial design should focus on clinical value and disease specificity.

Keywords: clinical trials; dementia with Lewy bodies; drug development; outcome measures; regulatory pathways.

PubMed Disclaimer

Conflict of interest statement

Dr. Sabbagh has ownership interest (stock or stock options) in NeuroTau, uMethod Health, Athira, TransDermix, Seq BioMarque, NeuroReserve, and Cortexyme/Quince Therapeutics and is a consultant for Alzheon, Roche‐Genentech, Eisai, KeifeRx, Lilly, Synaptogenix, NeuroTherapia, T3D, Signant Health, and Novo Nordisk. Dr. Sabbagh also receives royalties from Humanix and is on the Board of Directors for EIP Pharma. No other authors have any personal, financial, or institutional interest in any of the drugs, materials, or devices described in this manuscript. Author disclosures are available in the supporting information.

References

    1. Donaghy PC, McKeith IG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther. 2014;6(4):46. doi:10.1186/alzrt274 - DOI - PMC - PubMed
    1. McCann H, Stevens CH, Cartwright H, Halliday GM. alpha‐Synucleinopathy phenotypes. Parkinsonism Relat Disord. 2014;20(Suppl 1):S62‐S67. doi:10.1016/S1353-8020(13)70017-8 - DOI - PubMed
    1. Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70(11):1396‐1402. doi:10.1001/jamaneurol.2013.3579 - DOI - PMC - PubMed
    1. Hogan DB FK, Roberts JI, Maxwell CJ, et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci. 2016;43(Suppl 1):S83‐S95. doi:10.1017/cjn.2016.2 - DOI - PubMed
    1. Desai U, Chandler J, Kirson N, et al. Epidemiology and economic burden of Lewy body dementia in the United States. Curr Med Res Opin. 2022;38(7):1177‐1188. doi:10.1080/03007995.2022.2059978 - DOI - PubMed